[go: up one dir, main page]

PE20091829A1 - Encapsulacion de agentes biologicamente activos - Google Patents

Encapsulacion de agentes biologicamente activos

Info

Publication number
PE20091829A1
PE20091829A1 PE2009000607A PE2009000607A PE20091829A1 PE 20091829 A1 PE20091829 A1 PE 20091829A1 PE 2009000607 A PE2009000607 A PE 2009000607A PE 2009000607 A PE2009000607 A PE 2009000607A PE 20091829 A1 PE20091829 A1 PE 20091829A1
Authority
PE
Peru
Prior art keywords
monomer
organic phase
biologically active
active agents
bromide
Prior art date
Application number
PE2009000607A
Other languages
English (en)
Inventor
Irene Papanicolaou
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40944671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091829(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20091829A1 publication Critical patent/PE20091829A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

REFERIDA UN PROCEDIMIENTO PARA ENCAPSULAR AGENTES BIOLOGICAMENTE ACTIVOS EN UN VEHICULO EN FOMA DE PARTICULAS, DONDE DICHO PROCEDIMIENTO COMPRENDE: a) SOLUBILIZAR UN AGENTE ACTIVO TAL COMO UN PEPTIDO O UNA PROTEINA, UN ANTICUERPO O UN ANTICUERPO DE DOMINIO, EN PRESENCIA DE UN AGENTE DE APAREAMIENTO ION HIDROFOBO (HIP) TAL COMO DOCUSATO DE SODIO, BROMURO DE DIMETILDIOCTADECILAMONIO, 1,2-DIOLEOILOXI-3(TRIMETILAMONIO)PROPANO O BROMURO DE CETRIMONIO, Y EN UN DISOLVENTE ORGANICO PARA FORMAR UNA FASE ORGANICA; b) DISOLVER UN MONOMERO U OLIGOMERO DE UNA SUSTANCIA FORMADORA DE POLIMERO EN LA FASE ORGANICA FORMADA EN (a), DONDE EL MONOMERO COMPRENDE ALQUILCIANOACRILATO O BUTILCIANOACRILATO Y EL POLIMERO COMPRENDE POLI(CAPROLACTONA), POLI-L-LACTIDA, POLI(LACTIDA-CO-GLICOLIDA), ENTRE OTROS; c) FORMAR UNA EMULSION EN LA FASE ORGANICA FORMADA EN (b) EN UNA FASE ACUOSA CONTINUA PARA PERMITIR LA POLIMERIZACION DEL MONOMERO; Y d) OBTENER UN VEHICULO EN FORMA DE PARTICULAS
PE2009000607A 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos PE20091829A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
PE20091829A1 true PE20091829A1 (es) 2009-12-12

Family

ID=40944671

Family Applications (4)

Application Number Title Priority Date Filing Date
PE2009000607A PE20091829A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000609A PE20091965A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000608A PE20091964A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000606A PE20091882A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos

Family Applications After (3)

Application Number Title Priority Date Filing Date
PE2009000609A PE20091965A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000608A PE20091964A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
PE2009000606A PE20091882A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos

Country Status (11)

Country Link
US (1) US20110064821A1 (es)
EP (2) EP2271323A2 (es)
JP (1) JP2011522792A (es)
KR (3) KR20110015604A (es)
AR (4) AR071633A1 (es)
CA (1) CA2721241A1 (es)
CL (4) CL2009001076A1 (es)
PE (4) PE20091829A1 (es)
TW (4) TW201012490A (es)
UY (4) UY31810A (es)
WO (1) WO2009135853A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2271322A2 (en) * 2008-05-06 2011-01-12 Glaxo Group Limited Encapsulation of biologically active agents
WO2013021353A1 (en) 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
SG11201609955QA (en) * 2014-05-30 2016-12-29 Abbvie Deutschland Nanoencapsulation of antigen-binding molecules
US20170189344A1 (en) * 2014-05-30 2017-07-06 AbbVie Deutschland GmbH & Co. KG Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
WO2015191950A1 (en) * 2014-06-12 2015-12-17 Orbis Biosciences, Inc. Extended-release drug delivery compositions
AU2015280417B2 (en) 2014-06-24 2020-01-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
EP3703667A4 (en) * 2017-11-03 2021-08-04 The Trustees of Princeton University PAIRING OF HYDROPHOBIC IONS AND FLASH NANOPRECIPITATION FOR FORMULATIONS OF CONTROLLED RELEASE NANOVECTORS
US12186436B2 (en) 2018-07-19 2025-01-07 The Trustees Of Princeton University Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US20220031630A1 (en) * 2018-09-13 2022-02-03 The Brigham And Women's Hospital, Inc. Nanoparticle formulations and methods of their use
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833666A (en) 1986-12-24 1989-05-23 U.S. Philips Corporation Disc-record player suitable for scanning disc of different types
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
WO1994017789A1 (en) * 1993-02-15 1994-08-18 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
PT717617E (pt) * 1993-09-09 2001-04-30 Schering Ag Microparticulas com gas e pprincipios activos
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
CA2452382A1 (en) * 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
CA2531238C (en) 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
MXPA06006406A (es) 2003-12-05 2007-03-21 Adnexus Therapeutics Inc Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2.
CN101072553A (zh) 2004-09-14 2007-11-14 纳诺德尔技术股份有限公司 包含纳米颗粒的传送载体
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8227576B2 (en) 2006-03-30 2012-07-24 Glaxo Group Limited Antibodies against amyloid-β peptide
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2683801A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists

Also Published As

Publication number Publication date
AR071634A1 (es) 2010-06-30
CA2721241A1 (en) 2009-11-12
KR20110010758A (ko) 2011-02-07
UY31810A (es) 2009-12-14
WO2009135853A2 (en) 2009-11-12
EP2271323A2 (en) 2011-01-12
UY31807A (es) 2009-12-14
CL2009001077A1 (es) 2010-09-24
TW201012489A (en) 2010-04-01
UY31808A (es) 2009-12-14
AR072668A1 (es) 2010-09-15
AR071633A1 (es) 2010-06-30
PE20091964A1 (es) 2010-01-09
TW201006495A (en) 2010-02-16
EP2441447A1 (en) 2012-04-18
US20110064821A1 (en) 2011-03-17
WO2009135853A3 (en) 2011-05-12
CL2009001081A1 (es) 2010-09-24
UY31809A (es) 2009-12-14
TW201012490A (en) 2010-04-01
AR072359A1 (es) 2010-08-25
KR20110015604A (ko) 2011-02-16
PE20091882A1 (es) 2009-12-24
KR20110010760A (ko) 2011-02-07
CL2009001076A1 (es) 2010-09-24
PE20091965A1 (es) 2010-01-09
CL2009001080A1 (es) 2010-09-24
TW201012488A (en) 2010-04-01
JP2011522792A (ja) 2011-08-04

Similar Documents

Publication Publication Date Title
PE20091829A1 (es) Encapsulacion de agentes biologicamente activos
Mota et al. Broad overview of engineering of functional nanosystems for skin delivery
AR095081A1 (es) Compuestos químicos
PE20050926A1 (es) Composicion y forma de dosificacion que comprende una molecula anfifilica como un vehiculo de suspension
BRPI0801367A2 (pt) revestimento para dispositivo mÉdico tendo conjugado antitrombàtico
Rossi et al. Modeling the effect of nano-sized polymer particles on the properties of lipid membranes
MX2019006221A (es) Preparacion de complejos solidos de ciclodextrina para suministro de ingredientes farmaceuticos activos oftalmicos.
MX2017000783A (es) Revestimiento para catéter expandible intraluminal que proporciona contacto de transferencia de micro-depósitos de fármaco.
AR099756A1 (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso, composición farmacéutica
CO7240372A2 (es) Formulaciones farmacéuticas tópicas no acuosas
AR077155A1 (es) Nanodispersion, nanoparticulas y solucion
MX2014014662A (es) Manufactura de degarelix.
BRPI0518677A2 (pt) produto sàlido, processos para a produÇço de um produto sàlido e para a produÇço de uma nanodispersço estabilizada ou micela carregada, lÍquido translécido, mÉtodo de tratamento mÉdico, e, dispositivo para a produÇço de formulaÇÕes sàlidas de agentes biologicamente ativos lÍquidos
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
CL2014000418A1 (es) Particula de peptido que comprende un ligando en su superficie externa y uno o dos peptidos anfifilicos, los cuales comprenden un segmento peptidilo hidrofobico y un segmento peptidilo hidrofilico; y su uso para el suministro de un agente activo a una celula.
Gul et al. Functionalised nanostructures for transdermal delivery of drug cargos
Yong Study of interactions between polymer nanoparticles and cell membranes at atomistic levels
MX2007011039A (es) Sistema de solvente para aumentar la solubilidad de agentes farmaceuticos.
CO6280436A2 (es) Formulacion desinfectante liquida basada en un polimero acido y un agente tensoactivo anionico
ECSP17081071A (es) Composiciones de matriz polimérica tópicas que comprenden una alta concentración de hialuronato de sodio bio-fermentado y sus usos
CO2023002650A2 (es) Formas farmacéuticas sólidas de palbociclib
WO2014160387A3 (en) Compositions, methods and devices for local drug delivery
MX2020007321A (es) Proceso para liberar un ingrediente activo.
JP2016518358A5 (es)
BRPI0904083B8 (pt) método de obtenção de vesículas (nanocápsulas) com dupla camada polimérica e carga positiva, vesículas anfifílicas com dupla camada polimérica e carga positiva e seu uso

Legal Events

Date Code Title Description
FC Refusal